SECURITIES AND EXCHANGE COMMISSION
                       WASHINGTON, D.C.  20549
                                  
                                  
                              FORM 8-K


                           CURRENT REPORT

               PURSUANT TO SECTION 13 OR 15(d) OF THE
                   SECURITIES EXCHANGE ACT OF 1934


                    Date of Report:  July 2, 1996
                                  




                           MEDIMMUNE, INC.
       (Exact name of registrant as specified in its charter)



                  Commission File Number:  0-19131
                                  
                                  
          Delaware                          51-1555759
     (State of Incorporation)           (I.R.S. Employer
                                        Identification No.)



   35 West Watkins Mill Road, Gaithersburg, MD        20878
   (Address of principal executive offices)          (Zip Code)



   Registrant's telephone number, including area code: (301)417-0770





          No Exhibits are being filed with this report
                                  
                           MEDIMMUNE, INC.
                                  
                     Current Report on Form 8-K


ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained on the following
press releases dated July 1 and July 2, 1996.

                  MEDIMMUNE SUBMITS APPLICATION FOR
                   APPROVAL OF RESPIGAM IN CANADA
                                  
Gaithersburg, MD, July 1, 1996  --  MedImmune, Inc. (Nasdaq:MEDI)
today announced it has filed a new drug submission (NDS) with the
Drugs Directorate of the Health Protection Branch (HPB) of Health and
Welfare Canada, in support of marketing approval of RespiGam in
Canada.  RespiGam (Respiratory Syncytial Virus Immune Globulin
Intravenous (Human)) was recently licensed in the United States for
the prevention of serious lower respiratory tract infection caused by
respiratory syncytial virus (RSV) in children under 24 months of age
with bronchopulmonary dysplasia or a history of premature birth
(i.e., less than or equal to 35 weeks gestation; please see full
prescribing information).  This is the Company's first regulatory
application for marketing approval of RespiGamT outside of the United
States.

"RSV is one of the most important respiratory pathogens affecting
children worldwide," commented David M. Mott, President and Chief
Operating Officer.  "The Company's Canadian submission is exemplary
of the our strategy to expand the global reach of RespiGam beyond the
United States."

The Company has established a strategic alliance with the Wyeth-Ayerst
division of American Home Products Corporation, one of the leading
pharmaceutical companies focused on pediatric medicine worldwide, to
co-promote RespiGam in the United States. The Company has also
established a collaboration with Baxter Healthcare Corporation, one
of the largest producers and marketers of immune globulins worldwide,
to commercialize RespiGam outside of the United States, Canada and
Mexico.

MedImmune, Inc. is a biotechnology company focused on developing and
marketing products for the prevention and treatment of infectious
diseases and for use in transplantation medicine.  MedImmune
currently markets two products through its hospital-based sales force
and has six new products in clinical trials.  MedImmune is located in
Gaitersburg, MD.

This announcement may contain, in addition to historical information,
certain forward looking statements that involve risks and
uncertainties.  Such statements reflect management's current views
and are based on certain assumptions.  Actual results could differ
materially from those currently anticipated as a result of a number
of factors, including risks and uncertainties discussed in the
Company's filings with the U.S. Securities and Exchange Commission.
MedImmune cannot predict the timing or outcome of regulatory approval
processes.

                                #####

  MEDIMMUNE PLACES $60 MILLION IN 7% CONVERTIBLE SUBORDINATED NOTES
                                  
          -- Transaction Expected to Close July 8, 1996 --

Gaithersburg, MD, July 2, 1996  --  MedImmune, Inc. (Nasdaq:MEDI)
today announced it has agreed to privately place $60 million
principal amount of 7% convertible subordinated notes due 2003.  The
notes will be convertible into common stock at a price, subject to
adjustment in certain events, of $19.68 per share at any time 90 days
following the date of issuance.  MedImmune has granted Morgan Stanley
& Co. Incorporated, the initial purchasers of the notes, a 30-day
option to purchase an additional $9 million principal amount of notes
solely to cover over-allotments, if any.  The placement of the notes
is expected to close on July 8, 1996.

MedImmune intends to use the net proceeds for the offering for general
corporate purposes, including the funding of certain capital
expenditures associated with construction of a manufacturing
facility.

MedImmune, Inc. is a biotechnology company focused on developing and
marketing products for the prevention and treatment of infectious
diseases and for use in transplantation medicine.  MedImmune
currently markets two products through its hospital-based sales force
and has six new products in clinical trials.  MedImmune is located in
Gaithersburg, MD.

                                #####

                           SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.

                              MEDIMMUNE, INC.
                              (Registrant)


Date:  July 2, 1996           s/David M. Mott
                              President and Chief Operating Officer
                              (Principal financial and accounting
                                officer)
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 5995}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19131", "film-number": "96590281"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION
                       WASHINGTON, D.C.  20549
                                  
                                  
                              FORM 8-K

                           CURRENT REPORT

               PURSUANT TO SECTION 13 OR 15(d) OF THE
                   SECURITIES EXCHANGE ACT OF 1934

                    Date of Report:  July 2, 1996
                                  

                           MEDIMMUNE, INC.
       (Exact name of registrant as specified in its charter)

                  Commission File Number:  0-19131
                                  
                                  
          Delaware                          51-1555759
     (State of Incorporation)           (I.R.S. Employer
                                        Identification No.)

   35 West Watkins Mill Road, Gaithersburg, MD        20878
   (Address of principal executive offices)          (Zip Code)

   Registrant's telephone number, including area code: (301)417-0770

          No Exhibits are being filed with this report
                                  
                           MEDIMMUNE, INC.
                                  
                     Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained on the following
press releases dated July 1 and July 2, 1996.

                  MEDIMMUNE SUBMITS APPLICATION FOR
                   APPROVAL OF RESPIGAM IN CANADA
                                  
Gaithersburg, MD, July 1, 1996  --  MedImmune, Inc. (Nasdaq:MEDI)
today announced it has filed a new drug submission (NDS) with the
Drugs Directorate of the Health Protection Branch (HPB) of Health and
Welfare Canada, in support of marketing approval of RespiGam in
Canada.  RespiGam (Respiratory Syncytial Virus Immune Globulin
Intravenous (Human)) was recently licensed in the United States for
the prevention of serious lower respiratory tract infection caused by
respiratory syncytial virus (RSV) in children under 24 months of age
with bronchopulmonary dysplasia or a history of premature birth
(i.e., less than or equal to 35 weeks gestation; please see full
prescribing information).  This is the Company's first regulatory
application for marketing approval of RespiGamT outside of the United
States.

"RSV is one of the most important respiratory pathogens affecting
children worldwide," commented David M. Mott, President and Chief
Operating Officer.  "The Company's Canadian submission is exemplary
of the our strategy to expand the global reach of RespiGam beyond the
United States."

The Company has established a strategic alliance with the Wyeth-Ayerst
division of American Home Products Corporation, one of the leading
pharmaceutical companies focused on pediatric medicine worldwide, to
co-promote RespiGam in the United States. The Company has also
established a collaboration with Baxter Healthcare Corporation, one
of the largest producers and marketers of immune globulins worldwide,
to commercialize RespiGam outside of the United States, Canada and
Mexico.

MedImmune, Inc. is a biotechnology company focused on developing and
marketing products for the prevention and treatment of infectious
diseases and for use in transplantation medicine.  MedImmune
currently markets two products through its hospital-based sales force
and has six new products in clinical trials.  MedImmune is located in
Gaitersburg, MD.

This announcement may contain, in addition to historical information,
certain forward looking statements that involve risks and
uncertainties.  Such statements reflect management's current views
and are based on certain assumptions.  Actual results could differ
materially from those currently anticipated as a result of a number
of factors, including risks and uncertainties discussed in the
Company's filings with the U.S. Securities and Exchange Commission.
MedImmune cannot predict the timing or outcome of regulatory approval
processes.

                                #####

  MEDIMMUNE PLACES $60 MILLION IN 7% CONVERTIBLE SUBORDINATED NOTES
                                  
          -- Transaction Expected to Close July 8, 1996 --

Gaithersburg, MD, July 2, 1996  --  MedImmune, Inc. (Nasdaq:MEDI)
today announced it has agreed to privately place $60 million
principal amount of 7% convertible subordinated notes due 2003.  The
notes will be convertible into common stock at a price, subject to
adjustment in certain events, of $19.68 per share at any time 90 days
following the date of issuance.  MedImmune has granted Morgan Stanley
& Co. Incorporated, the initial purchasers of the notes, a 30-day
option to purchase an additional $9 million principal amount of notes
solely to cover over-allotments, if any.  The placement of the notes
is expected to close on July 8, 1996.

MedImmune intends to use the net proceeds for the offering for general
corporate purposes, including the funding of certain capital
expenditures associated with construction of a manufacturing
facility.

MedImmune, Inc. is a biotechnology company focused on developing and
marketing products for the prevention and treatment of infectious
diseases and for use in transplantation medicine.  MedImmune
currently markets two products through its hospital-based sales force
and has six new products in clinical trials.  MedImmune is located in
Gaithersburg, MD.

                                #####

                           SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.

                              MEDIMMUNE, INC.
                              (Registrant)

Date:  July 2, 1996           s/David M. Mott
                              President and Chief Operating Officer
                              (Principal financial and accounting
                                officer)